Stem and stromal cells are expected to revolutionize the treatment of today’s severe and incurable diseases. NextCell develops pioneering stromal cell therapies for the treatment of autoimmune and inflammatory diseases. NextCell's drug candidate, ProTrans, is at the forefront of our development for the treatment of type 1 diabetes.
NextCell's Product Portfolio
NextCell develops novel stromal cell therapies, with a primary focus on type 1 diabetes. The lead candidate ProTrans, is based on NextCell patented selection algorithm. NextCell also runs Cellaviva, Scandinavia's largest private stem cell bank.
NextCell is a Swedish biopharmaceutical company running two business areas with the same core – stem and stromal cells from umbilical cord. NextCell is focusing on research and development of novel stromal cell therapies and also runs a tissue establishment and primary biobank, classified as a healthcare provider.
Repeated treatment with ProTrans is immunologically safe
NextCell Pharma AB ("NextCell" or the "Company") today announces that multiple treatments with ProTrans cell therapy does not induce donor specific antibodies in type-1 diabetes patients. A detailed analysis of how the immune system reacts to infusion of ProTrans cells show that treatment can be given to any adult type 1 diabetic, irrespective of pre-existing HLA antibodies.
NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Year-End Report for the period September 1, 2022 – August 31, 2023. The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.
NextCell signs an agreement for a new tissue product
NextCell Pharma AB (“NextCell” or “the company”) announces that the company has signed an agreement with the Finnish biotechnology company Linio to warehouse and distribute Tience® in Sweden. The value of the agreement for the first year amounts to approximately 400 000 SEK in fixed remuneration and a variable remuneration per product delivered. Tience is a tissue product that is injected to combat scarring and can also be used for aesthetic purposes such as skin rejuvenation and to combat wrinkles. The product is marketed and sold by Linio to clinics and hospitals.
NextCell Pharma presents at the Advanced Therapies Europe conference
NextCell Pharma participates in Advanced Therapies Europe, a European conference in Portugal on advanced cell therapies. NextCell's CSO Dr. Lindsay Davies will talk about NextCell's platform technology and the internationally recognized research generated during the development of drug product ProTrans for type 1 diabetes.